AliveDx Suisse S.A. and BioAnalytica S.A. Sign Distribution Agreement for Greece and Cyprus

AliveDx Suisse S.A. and BioAnalytica S.A. have signed a distribution agreement, which will enable BioAnalytica to distribute the MosaiQ® solution in Greece and Cyprus. The distribution agreement takes effect immediately.

This strategic partnership underscores AliveDx’s commitment to expanding its geographical reach and creating clinical and economical value for clinicians, aiding them in reducing diagnosis time. This collaboration will allow both parties to enhance patient care and deliver high-quality services to the healthcare sector in Southern Europe.

The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.

“We are proud to announce our partnership with another key player in the European Union. We look forward to collaborating with BioAnalytica and supporting laboratorians, clinicians, and patients in the region,” said Manuel O. Méndez, AliveDx’s CEO.

BioAnalytica is a leader in the development and expansion of the biotechnology sector in Greece and Cyprus, consistently seeking innovation and scientific excellence. The company offers innovative tools for healthcare, production, environment, and many other applications.

“We are thrilled about our new partnership with AliveDx, which enables us to distribute the innovative MosaiQ multiplexing microarray assay technology for diagnosing autoimmune diseases. This collaboration marks a significant milestone for BioAnalytica as we join forces with a company renowned for its excellence, commitment to quality, and cutting-edge technology. Together, we aim to expand our reach, enhance our service offerings, and bring even greater value to our customers. We look forward to a prosperous and successful partnership focused on advancing autoimmunity solutions with the latest technological innovations,” said Mr. Stavros Souyannis, CEO of BioAnalytica.

To learn more, please visit the BioAnalytica website.

Trending Topics

Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.